Inhibition of Passive Cutaneous Anaphylaxis-Associated Scratching Behavior by μ-Opioid Receptor Antagonists in ICR MiceInagaki N. · Nakamura N. · Nagao M. · Kawasaki H. · Nagai H.
Department of Pharmacology, Gifu Pharmaceutical University, Gifu, Japan
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Background: Itching in humans is attenuated by µ-opioid receptor antagonists. ICR mice display increases in scratching behavior upon induction of IgE-mediated passive cutaneous anaphylaxis (PCA), or intradermal injection of compound 48/80 or histamine. Methods: Cutaneous reactions were induced in ICR mice by IgE-mediated PCA, compound 48/80 and histamine, and the scratching behavior associated with the cutaneous reactions was evaluated. Results: Naloxone and nalmefene reduced the incidence of scratching behavior associated with PCA. Naloxone also inhibited the induction of scratching behavior caused by compound 48/80 and histamine. Naloxone did not affect the increase in vascular permeability caused by PCA and injection of compound 48/80. Conclusion: Scratching behavior in mice may be induced by a sensation or a mechanism similar to itching in humans and should become a useful model for examining itching in humans.
© 2000 S. Karger AG, Basel
- Kuraishi Y, Nagasawa T, Hayashi K, Satoh M: Scratching behavior induced by pruritogenic but not algesiogenic agents in mice. Eur J Pharmacol 1995;275:229–233.
- Inagaki N, Nakamura N, Nagao M, Musoh K, Kawasaki H, Nagai H: Participation of histamine H1 and H2 receptors in passive cutaneous anaphylaxis-induced scratching behavior in ICR mice. Eur J Pharmacol 1999;367:361–371.
- Inagaki N, Goto S, Nagai H, Koda A: Homologous passive cutaneous anaphylaxis in various strains of mice. Int Arch Allergy Appl Immunol 1986;81:58–62.
- Lei HY, Lee SH, Leir SH: Antigen-induced anaphylactic death in mice. Int Arch Allergy Immunol 1996;109:407–412.
Duffy BL: Itching as a side-effect of epidural morphine. Anaesthesia 1981;36:67.
- Ballantyne JC, Loach AB, Carr DB: Itching after epidural and spinal opiates. Pain 1988;33:149–160.
- Bergasa NV, Alling DW, Talbot TL, Swain MG, Yurdaydin C, Turner ML, Schmitt JM, Walker EC, Jones EA: Effects of naloxone infusions in patients with the pruritus of cholestasis. A double-blind, randomized, controlled trial. Ann Intern Med 1995;123:161–167.
- Wolfhagen FH, Sternieri E, Hop WC, Vitale G, Bertolotti M, Van Buuren HR: Oral naltrexone treatment for cholestatic pruritus: A double-blind, placebo-controlled study. Gastroenterology 1997;113:1264–1269.
- Thomas DA, Williams GM, Iwata K, Kenshalo DR Jr , Dubner R: The medullary dorsal horn. A site of action of morphine in producing facial scratching in monkeys. Anesthesiology 1993;79:548–554.
- Tohda C, Yamaguchi T, Kuraishi Y: Intracisternal injection of opioids induces itch-associated response through μ-opioid receptors in mice. Jpn J Pharmacol 1997;74:77–82.
- Kuraishi Y, Yamaguchi T, Miyamoto T: Itch-scratch responses induced by opioids through central μ opioid receptors in mice. J Biomed Sci 2000;7:248–252.
Sakurai T, Inagaki N, Nagai H: The effect of anti-tumor necrosis factor (TNF)-α monoclonal antibody on allergic cutaneous late phase reaction in mice. Life Sci 1994;54:PL291–295.
- Inagaki N, Goto S, Yamasaki M, Nagai H, Koda A: Studies on vascular permeability increasing factors involved in 48-hour homologous PCA in the mouse ear. Int Arch Allergy Appl Immunol 1986;80:285–290.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.